Scholarlink

Background <p><i>Acinetobacter baumannii</i> is a significant opportunistic pathogen causing severe nosocomial infections that poses increasing clinical challenges due to escalating multidrug resistance. Phage therapy has emerged as a promising alternative strategy to combat multidrug-resistant (MDR) infections.</p> Results <p>In this study, a lytic phage targeting ST208/KL2-type <i>A. baumannii</i> strain Ac28 was isolated and purified from hospital sewage. Whole-genome sequencing and a bioinformatics analysis successfully identified a novel podovirus, designated “vB_AbaA_SWMUZ8”. A host-range analysis demonstrated a lysis rate of 58.33% against 84 clinically derived <i>A. baumannii</i> isolates of diverse multilocus sequence types, with particularly high efficacy against 88% of ST208 strains. Notably, vB_AbaA_SWMUZ8 lysed 100% of geographically co-localized isolates. It inhibited the growth of MDR <i>A. baumannii</i> strain Ac28 in vitro and improve survival rates in a <i>Galleria mellonella</i> infection model.</p> Conclusions <p>In this work, we identified a therapeutically promising lytic phage and provided evidence for the phage-based control of MDR <i>A. baumannii</i> infections.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Isolation and characterization of novel bacteriophage, vB_AbaA_SWMUZ8, targeting multidrug-resistant Acinetobacter baumannii strains

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月18日

查看全文
  • Jing Li,
  • Chunhong Yang,
  • Ruyi Yang,
  • Kaitao Zhang,
  • Pan Yang,
  • Ling Yin,
  • Jinping Zhang,
  • Zhangyong Song

摘要

Background

Acinetobacter baumannii is a significant opportunistic pathogen causing severe nosocomial infections that poses increasing clinical challenges due to escalating multidrug resistance. Phage therapy has emerged as a promising alternative strategy to combat multidrug-resistant (MDR) infections.

Results

In this study, a lytic phage targeting ST208/KL2-type A. baumannii strain Ac28 was isolated and purified from hospital sewage. Whole-genome sequencing and a bioinformatics analysis successfully identified a novel podovirus, designated “vB_AbaA_SWMUZ8”. A host-range analysis demonstrated a lysis rate of 58.33% against 84 clinically derived A. baumannii isolates of diverse multilocus sequence types, with particularly high efficacy against 88% of ST208 strains. Notably, vB_AbaA_SWMUZ8 lysed 100% of geographically co-localized isolates. It inhibited the growth of MDR A. baumannii strain Ac28 in vitro and improve survival rates in a Galleria mellonella infection model.

Conclusions

In this work, we identified a therapeutically promising lytic phage and provided evidence for the phage-based control of MDR A. baumannii infections.